Loading
A phase 1 trial of Vispacabtagene regedleucel run by Caribou Biosciences, Inc., active and no longer recruiting.
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) is a phase 1 interventional study registered as NCT04637763 by Caribou Biosciences, Inc., with 72 participants planned, started 2021-05-26. Conditions recorded: Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma and B Cell Non-Hodgkin's Lymphoma. Interventions recorded: CB-010, Cyclophosphamide and Fludarabine.
Shares Caribou Biosciences and the tag pipeline.
Shares Caribou Biosciences and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/